Fig 1.
Consort Flow Diagram of trial from enrollment through analysis.
Fig 2.
PI-RADS Scoring System.
Fig 3.
SQS Scoring System, Step 1: Calculate raw score by adding points for each finding listed.
Score range is between 0–4.
Fig 4.
SQS Scoring System, Step 2: Calculate Overall SQS suspicion score.
Select PZ or TZ then use the raw score to select the initial level of suspicion. Next move left to right taking into account the T2, ADC, DCE findings. You must meet all the criteria on each line to obtain the overall suspicion score on the right side of the table; otherwise use the lower score.
Fig 5.
5-point scale: Overall SQS Score and PI-RADS use the same terminology for grading.
Fig 6.
Zonal Anatomy.
Fig 7.
T2 sequence with a low signal intensity in Zone 3L. B. DWI with corresponding ADC restriction C. DCE with early arterial uptake. D. MR US fusion directed biopsy detected Gleason 3+4, 2.5 mm. Please see supplemental report regarding specific lesion based reporting.
Table 1.
Cancer detection rates for prostate cancer and clinically significant prostate cancer stratified by scoring system.
Fig 8.
Distribution of lesions reported on mpMRI stratified by SQS Score.
Fig 9.
Distribution of lesions on mpMRI stratified by PI-RADS Score.
Fig 10.
ROC curve analysis: Patient-based.
Fig 11.
ROC curve analysis: Lesion-based.
Table 2.
Positive Predictive Value, Negative Predictive Value, Sensitivity and Specificity at each cut point in each scoring system for the detection of clinically significant prostate cancer: Patient-level analysis.
Table 3.
Positive Predictive Value, Negative Predictive Value, Sensitivity and Specificity at each cut point in each scoring system for the detection of clinically significant prostate cancer: Lesion-level analysis.